DEG impurity above limit found in another cough syrup, Haryana issues alert

Published On 2025-11-10 10:30 GMT | Update On 2025-11-10 10:30 GMT

Haryana: Barely weeks after the ColdRif - linked child deaths in Madhya Pradesh shocked the nation, Haryana has issued a public health alert over another cough syrup formulation in which diethylene glycol (DEG) impurity was detected above permissible limits.

Health Minister Arti Singh Rao said on Saturday that the cough syrup formulation -- "Planokuf D" syrup containing cetirizine hydrochloride, phenylephrine hydrochloride and dextromethorphan hydrobromide, and manufactured by Shreya Lifesciences Private Limited -- has been found to contain DEG impurity beyond permissible limits.

The warning came after the Food and Drugs Administration (FDA), Haryana received an official communication from the Central Drugs Standard Control Organisation's (CDSCO) sub-zonal office in Guwahati.

The affected batch, bearing number R25053101, was manufactured in February and is set to expire in January 2027. The product has been declared adulterated and Not of Standard Quality (NSQ), the statement said.

The minister said the FDA has directed all senior drugs control officers (SDCOs) and drugs control officers (DCOs) across Haryana to maintain a strict vigil on the movement of the said drug in the market.

Officers have been instructed to draw samples, seize any remaining stock and initiate strict action wherever the product is found.

The State Drugs Controller has ordered an immediate ban on the sale, distribution, prescription and use of the above-mentioned batch of the product throughout Haryana.

Retailers, wholesalers, distributors, hospitals and medical practitioners have been strictly advised not to sell, stock, prescribe or administer the affected batch under any circumstances.

DEG is a toxic chemical known to cause serious health complications, including acute poisoning, kidney failure, neurological disorders and even death, particularly among children. Rao has urged the public to remain vigilant and report any availability of the affected batch in the market to the nearest drugs control officer.

Article Source : With inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

DEG impurity above limit found in another cough syrup, Haryana issues alert

Similar News

Cohance Lifesciences appoints Rahul Pradhan as VP - Operations to head API Unit III, Ankleshwar

Dr Sujiv Nair takes over as Chief People Officer of MSN Group

Intas Pharma ropes in Sujit Mandal as Associate Vice President - Manufacturing Finance

USFDA concludes inspection at Marksans Pharma Goa facility with zero Form 483 observation

Merck inks pact with Dr Falk Pharma for certain development, commercialization rights to MK 8690

Biocon gets 2 USFDA observations for Visakhapatnam facility

Mankind Pharma net profit declines 21 percent to Rs 520 crore in Q2